About: SARS-CoV-2 infection serology: a useful tool to overcome lockdown?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 infection serology: a useful tool to overcome lockdown?
Creator	Ciotti, Marco Bernardini, Sergio Andreoni, Massimo Grelli, Sandro Miano, Roberto Nuccetelli, Marzia Pieri, Massimo
Source	Medline; PMC
abstract	The outbreak of 2019 novel coronavirus disease (Covid-19) caused by SARS-CoV-2 has spread rapidly, inducing a progressive growth in infected patients number. Social isolation (lockdown) has been assessed to prevent and control virus diffusion, leading to a worldwide financial and political crisis. Currently, SARS-CoV-2 RNA detection in nasopharyngeal swab takes place by real-time PCR (RT-qPCR). However, molecular tests can give some false-negative results. In this context, serological assays can be useful to detect IgG/IgM antibodies, to assess the degree of immunization, to trace the contacts, and to support the decision to re-admit people at work. A lot of serological diagnostic kits have been proposed on the market but validation studies have not been published for many of them. The aim of our work was to compare and to evaluate different assays analytical performances (two different immunochromatographic cards, an immunofluorescence chromatographic card, and a chemiluminescence-automated immunoassay) on 43 positive samples with RT-qPCR-confirmed SARS-CoV-2 infection and 40 negative control subjects. Our data display excellent IgG/IgM specificities for all the immunocromatographic card tests (100% IgG and 100% IgM) and for the chemiluminescence-automated assay (100% IgG and 94% IgM); IgG/IgM sensitivities are moderately lower for all methods, probably due to the assay viral antigen’s nature and/or to the detection time of nasopharyngeal swab RT-qPCR, with respect to symptoms onset. Given that sensitivities (around 94% and 84% for IgG and IgM, respectively) implicate false-negative cases and given the lack of effective vaccines or treatments, the only currently available procedure to reduce SARS-CoV-2 transmission is to identify and isolate persons who are contagious. For this reason, we would like to submit a flowchart in which serological tests, integrated with nasopharyngeal swab RT-qPCR, are included to help social and work activities implementation after the pandemic acute phase and to overcome lockdown.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1038/s41420-020-0275-2
bibo:pmid	32501411
has license	cc-by
sha1sum (hex)	9c32884c4f14cea35fb8d036697c72fc12adbc9b
schema:url	https://doi.org/10.1038/s41420-020-0275-2
resource representing a document's title	SARS-CoV-2 infection serology: a useful tool to overcome lockdown?
has PubMed Central identifier	PMC7249039
has PubMed identifier	32501411
schema:publication	Cell Death Discov
resource representing a document's body	covid:9c32884c4f14cea35fb8d036697c72fc12adbc9b#body_text
is schema:about of	named entity 'serological' named entity 'IgG' named entity 'specificities' named entity 'SARS-CoV-2' named entity 'effective' named entity 'inducing' named entity 'data' named entity '2019' named entity 'transmission' named entity 'aim' named entity 'immunochromatographic' named entity 'overcome' named entity 'PEOPLE' named entity 'PLACE' named entity 'TREATMENTS' named entity 'INTEGRATED' named entity 'VIRAL ANTIGEN' named entity 'SPECIFICITIES' named entity 'PERFORMANCES' named entity 'immunization' named entity 'chromatographic' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'control' named entity 'positive' named entity 'card' named entity 'acute' named entity 'SARS-CoV-2' named entity 'vaccines' named entity 'assessed' named entity 'phase' named entity 'assays' named entity 'IgM' named entity 'worldwide' named entity 'IgG' named entity 'identify' named entity 'immunofluorescence' named entity 'antibodies' named entity 'real-time PCR' named entity 'virus' named entity 'SARS-CoV-2' named entity 'flowchart' named entity 'SARS-CoV-2' named entity 'immunoassay' named entity 'coronavirus disease' named entity 'negative control' named entity 'RT-qPCR' named entity 'antigen' named entity 'serological tests' named entity 'false-negative' named entity 'IgG/IgM' named entity 'RT-qPCR' named entity 'lockdown' named entity 'serological' named entity 'support' named entity 'recombinant proteins' named entity 'RBD' named entity 'Hangzhou' named entity 'hospital laboratories' named entity 'IgG' named entity 'social distance' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'Padova' named entity 'social distancing' named entity 'infection' named entity 'recombinant' named entity 'infection' named entity 'IgG' named entity 'antibodies' named entity 'RT-qPCR' named entity '2019-nCoV' named entity 'immunochromatographic' named entity 'mucous membrane' named entity 'IgG'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software